科华生物：高管薪酬严格按公司制度确定，与子公司交易不构成关联交易

Group 1 - The core issue raised by investors concerns the high salaries of four executives at Tianlong Technology, a subsidiary of Kehua Bio, and whether these salaries are also compensated by Tianlong Technology [1] - Kehua Bio responded that the salaries of senior management are determined according to the company's compensation management policy and relevant regulations, ensuring compliance with legal standards [1] - The company clarified that transactions with subsidiaries within the consolidated financial statements do not constitute related party transactions, emphasizing adherence to laws and internal regulations [1]